Key result
Neutral endopeptidase inhibition increased circulating endothelin-1 (P<0.01) and ANP (P<0.01) without adversely affecting systemic or renal hemodynamics in heart transplant patients.
Why the study?
Does acute neutral endopeptidase (NEP) inhibition alter hemodynamic, renal, and hormonal responses in chronic, stable heart transplant patients?
RCT (n=7)
Double-blind
Does acute neutral endopeptidase (NEP) inhibition alter hemodynamic, renal, and hormonal responses in chronic, stable heart transplant patients?
p-value: p=<0.01
Acute NEP inhibition in stable heart transplant patients increases ANP and promotes natriuresis and diuresis without adverse systemic or renal hemodynamic effects, despite an increase in endothelin-1.
No takes yet. Share an insight, caveat, or question.
Supports acute NEP inhibition safety in stable heart transplant patients; extends hormonal response data to this population.
Piquard et al. (2002) conducted an RCT in Chronic, stable heart transplant (n=7). Neutral endopeptidase (NEP) inhibition vs. Placebo was evaluated on Circulating endothelin-1 (p=<0.01). Neutral endopeptidase inhibition increased circulating endothelin-1 (P<0.01) and ANP (P<0.01) without adversely affecting systemic or renal hemodynamics in heart transplant patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: